A carregar...
Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced bre...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2727787/ https://ncbi.nlm.nih.gov/pubmed/19707428 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|